Renal BCGosis managed conservatively with antituberculous medications

Intravesical Bacillus Calmette–Guérin (BCG) therapy for nonmuscle-invasive bladder cancer rarely leads to the development of granulomatous renal masses (renal BCGosis). The management includes nephroureterectomy, antitubercular therapy (ATT), or both. Here, we present a case of a 62-year-old male wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmekresh, Amr, Al Shaikh, Yazan, Alhayek, Rafe, Saeedi, Yaser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252775/
https://www.ncbi.nlm.nih.gov/pubmed/37304506
http://dx.doi.org/10.4103/ua.ua_117_22
Descripción
Sumario:Intravesical Bacillus Calmette–Guérin (BCG) therapy for nonmuscle-invasive bladder cancer rarely leads to the development of granulomatous renal masses (renal BCGosis). The management includes nephroureterectomy, antitubercular therapy (ATT), or both. Here, we present a case of a 62-year-old male who was treated with ATT alone for renal masses. Six months after intravesical BCG therapy for transitional cell carcinoma, he developed high-grade fever and night sweat and had multiple renal parenchymal hypodensities on computed tomography (CT) scan. Repeat CT scan 6 months after ATT revealed full resolution of renal hypodensities. This case report highlights the importance of follow-up for early detection of adverse effects of BCG treatment.

Ejemplares similares